Liu Wentong, Tang Qianwen, Zhang Wei, Hua Ailian, Ye Xiaolan
School of Pharmacy, Hangzhou Normal University, Hangzhou, China.
Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
Ren Fail. 2025 Dec;47(1):2540563. doi: 10.1080/0886022X.2025.2540563. Epub 2025 Aug 7.
Medications contribute to about a quarter of acute kidney injury (AKI) cases among patients in hospitals. The impact of AKI is substantial on both families and society, and it has become a worldwide public health concern. Recently, a new framework for drug-induced acute kidney injury (DI-AKI) classification has been proposed. According to this new framework, drugs are divided into four categories. Thus, we explain the mechanism thoroughly and give examples of drugs or drug categories linked to the classes in the new framework. Furthermore, a patient's condition may dynamically shift between categories. At the same time, we also took into account some susceptibility factors. These susceptibility factors may drive inter-class variation. The new classification system may shed new light on the mechanism of DI-AKI for clinicians and researchers.
在医院患者中，药物导致的急性肾损伤（AKI）病例约占四分之一。急性肾损伤对家庭和社会都有重大影响，已成为全球公共卫生问题。最近，有人提出了一种药物性急性肾损伤（DI-AKI）分类的新框架。根据这个新框架，药物被分为四类。因此，我们深入解释了其机制，并给出了与新框架中各类别相关的药物或药物类别的例子。此外，患者的病情可能会在不同类别之间动态变化。同时，我们也考虑了一些易感因素。这些易感因素可能导致类别间的差异。新的分类系统可能会为临床医生和研究人员对药物性急性肾损伤的机制提供新的见解。
